Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2014; 20(40): 14581-14588
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14581
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14581
Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013
Hwi Young Kim, Won Kim, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 156-707, South Korea
Author contributions: Kim HY collected data, reviewed literatures, and wrote the manuscript; Kim W designed this review, appraised critically and revised the manuscript.
Correspondence to: Won Kim, MD, PhD, Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 156-707, South Korea. drwon1@snu.ac.kr
Telephone: +82-2-8702233 Fax: +82-2-8312826
Received: October 29, 2013
Revised: February 18, 2014
Accepted: May 19, 2014
Published online: October 28, 2014
Processing time: 365 Days and 17 Hours
Revised: February 18, 2014
Accepted: May 19, 2014
Published online: October 28, 2014
Processing time: 365 Days and 17 Hours
Core Tip
Core tip: Hepatitis B reactivation is a serious complication of anticancer chemotherapy, affecting both hepatitis B surface antigen-positive and anti-hepatitis B core antibody-positive patients. Although treatment of hepatitis B has been dramatically improved in the past decade, management of hepatitis B virus (HBV) reactivation remains unsatisfactory. This review covers updates from recent reports, unresolved issues and future perspectives on HBV reactivation.